/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Minerva Neurosciences, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.33 0.0246(2.46%) NERV at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 3.25
Highest Today 3.355
Today’s Open 3.355
Prev. Close 3.25
52 Week High 6.41
52 Week Low 1.15
Day’s Range: Low 3.25 High 3.355
52-Week Range: Low 1.15 High 6.41
1 day return -
1 Week return -19.02
1 month return -10.02
3 month return +59.61
6 month return +78.49
1 year return +39.49
3 year return -1.77
5 year return -84.79
10 year return -

Institutional Holdings

Federated Hermes Inc 19.32

Federated Hermes Kaufmann R 12.98

Federated Hermes Kaufmann Small Cap A 10.97

Federated Hermes Kaufmann Growth 10.37

Federated Hermes Kaufmann Small Cap Grow 8.65

Vanguard Group Inc 3.60

Vanguard Total Stock Mkt Idx Inv 2.46

Renaissance Technologies Corp 1.59

Geode Capital Management, LLC 1.08

BlackRock Inc 1.04

Vanguard Institutional Extnd Mkt Idx Tr 0.73

Fidelity Total Market Index 0.41

Federated Hermes Kaufmann II P 0.38

Fidelity Extended Market Index 0.38

Apella Capital, LLC 0.30

Extended Equity Market Fund K 0.29

State Street Corp 0.24

LUX IM Global Medtech HX 0.19

ADAR1 Capital Management LLC 0.18

Morgan Stanley - Brokerage Accounts 0.16

Fidelity Series Total Market Index 0.10

Fidelity Nasdaq Composite Index 0.07

Spartan Extended Market Index Pool F 0.07

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - L 0.07

NT Ext Equity Mkt Idx Fd - NL 0.05

Spartan Total Market Index Pool G 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

Extended Equity Market Fund M 0.04

Tower Research Capital LLC 0.03

UBS Group AG 0.01

SBI Securities Co Ltd 0.00

Northwestern Mutual Wealth Management Co 0.00

BNP Paribas Arbitrage, SA 0.00

Bank of America Corp 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

Royal Bank of Canada 0.00

Citadel Advisors Llc 0.00

Northern Trust Corp 0.00

Wells Fargo & Co 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 26.92 M

PB Ratio 2.6783

PE Ratio 0.0

Enterprise Value 16.95 M

Total Assets 37.14 M

Volume 67339

Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:41175600 41.2M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:41175600 41.2M

Annual Net worth FY24:1438865000 1438.9M, FY23:-27708951 -27.7M, FY22:-38986026 -39.0M, FY21:-49905952 -49.9M, FY20:1940771 1.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:42218 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1361 -0.0M, Q2/2025:-1360 -0.0M, Q1/2025:21109 0.0M, Q3/2024:-5618 -0.0M, Q2/2024:-7746 -0.0M

Quarterly Net worth Q3/2025:-2743954 -2.7M, Q2/2025:-3258588 -3.3M, Q1/2025:-3752972 -3.8M, Q3/2024:22513205 22.5M, Q2/2024:-8233487 -8.2M

Fund house & investment objective

Company Information Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Dr. Remy Luthringer Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow